AKEBIA THERAPEUTICS INC (AKBA) Stock Income Statement
NASDAQ:AKBA - Nasdaq - US00972D1054 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 160.18M | 194.62M | 292.50M | 211.70M | 294.60M | |||
| Cost Of Goods | 26.16M | 39.74M | 22.50M | 103.10M | 132.20M | |||
| Gross Profit | 134.03M | 154.88M | 270.00M | 108.50M | 162.40M | |||
| Operating Expenses | 180.24M | 199.35M | 304.70M | 358.10M | 405.30M | |||
| Research and Development | 37.65M | 63.08M | 130.00M | 147.90M | 218.50M | |||
| Selling, General, and Administrative Expenses | 106.55M | 100.23M | 138.60M | 174.10M | 154.10M | |||
| Operating Income | -46.21M | -44.48M | -34.70M | -249.50M | -242.80M | |||
| Interest Income/Expense | -18.18M | -6.03M | -15.70M | -19.90M | -8.90M | |||
| Other Income/Expense | -236.00K | 887.00K | 3.10M | 2.40M | 1.90M | |||
| Non Recurring Items | -4.78M | -2.31M | -47.00M | -15.00M | -135.00M | |||
| Income Before Taxes | -69.41M | -51.92M | -94.20M | -282.00M | -384.80M | |||
| Income Tax | N/A | N/A | 0.00 | 0.00 | 0.00 | |||
| Net Income | -69.41M | -51.92M | -94.20M | -282.00M | -384.80M | |||
| EBITDA | -8.71M | -6.85M | 2.99M | -211.53M | -209.20M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.33 | -0.28 | -0.52 | -1.70 | -2.78 | |||
| Non GAAP EPS | -0.33 | -0.28 | -0.44 | -1.70 | -1.93 | |||
| Statistics | ||||||||
| Gross Profit Margin | 83.67% | 79.58% | 92.31% | 51.25% | 55.13% | |||
| Profit Margin | -43.33% | -26.68% | -32.21% | -133.21% | -130.62% | |||
| Operating Profit Margin | -28.85% | -22.85% | -11.86% | -117.86% | -82.42% | |||
All data in USD